It is a truth universally acknowledged that a biotech in possession of a mid-stage GLP-1 must be in want of a partner. Structure Therapeutics is no exception. With Phase 2 trials of its obesity pill set to read out soon, it's interested in cutting deals. Endpoints News caught up with CEO Ray Stevens while he was attending the annual meeting of the
American Diabetes Association last month in Chicago. Aleniglipron, formerly coded GSBR-1290, is in two Phase 2 obesity trials called ACCESS and ACCESS II. Their purpose is dose-finding for Phase 3, with 120 mg in ACCESS and 180 mg and 240 mg in ACCESS II, Stevens said. “We’re really looking for that upper dose," he added. By the end of this year, Structure expects to report topline data on weight loss at around eight months, and then aims to start Phase 3 in 2026. |